• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Govtempdiary

Govtempdiary is a prominent source of news for Central government employees

  • Home
  • Aicpin
  • Recent Post
  • DA From July 2023
  • Pay Matrix
  • Dopt orders
  • Recent Govt Orders
  • DA News
8th Pay commission NewsDA from July 2023


Pay Matrix7th Pay Commission Calculator
Dopt Order 2023Recent govt order
8th Pay commission NewsMACP Calculator
Gratuity CalculatorKV Fees Online
CGE Holiday 2023 PDFCGHS Rate list PDF
AicpinDA From July 2023

CGHS Implements CDSCO Guidelines for Procurement & Issue of Bio-similar Medicines

March 3, 2023 Eliza

The Indian Ministry of Health and Family Welfare’s Central Government Health Scheme (CGHS) has issued a policy on bio-similar medicines for procurement and issuance to CGHS beneficiaries. The regulatory authority for drug approval in India, the Central Drug Standard Control Organization’s Biological Division, defines bio-similar medicines as similar in terms of quality, safety, and efficacy to an approved reference biological product based on comparability. The policy states that bio-similar medicines procured and issued to CGHS beneficiaries should be on par with the reference authorized biologic/original biologic molecule/formulation of biologic medicine in accordance with the CDSCO’s guidelines. The memorandum was approved by Dr. Anjana Rajkumar, the Director of CGHS, on 8th February 2023.

Policy on Bio-similar medicines in CGHS for purpose of procurement and issue to CGHS Beneficiaries

File No. 1-1/22-23/CGHS/MSDI/3570884/2023
भारत सरकार
स्‍वास्‍थ्‍य और परिवार कल्‍याण मंत्रालय
महानिदेशालय, के.स.स्‍वा.यो.
निर्माण भवन, मौलाना आजाद रोड, नई दिल्‍ली

545-ए निर्माण भवन, नई दिल्‍ली
Dated:08-02-2023

कार्यालय ज्ञापन/ OFFICE MEMORANDUM

Subject: Policy on Bio-similar medicines in CGHS for purpose of procurement and issue to CGHS Beneficiaries

The Central Drug Standard Control Organization’s (CDSCO) Biological Division is the regulatory authority for approval of drugs in India, and issues guidelines of bio-similar medicine/drugs. The guidelines define biosimilar as “a similar biologic product which is similar in terms of quality, safety and efficacy to an approved Reference’ Biological product based on comparability”.

Therefore, it has been decided that, for the purpose of procurement & issue to CGHS beneficiaries, the bio-similar medicine shall be at par with the reference authorized biologic/original biologic molecule/formulation of biologic medicine on the lines of guideline issued by CDSCO in this regard.

Signed by Anjana Rajkumar
Date: 08-02-2023 14:40:01
Reason: Approved
(डा. अंंजना राजकुमार)
Director CGHS
Tel No. 011-23062800

Get Free email updates

Enter your email to subscribe to notifications from this site

Share this:

  • Email
  • Tweet
  • WhatsApp

Related

Filed Under: CGE Latest News, CGHS, Recent govt orders March 3, 2023

Primary Sidebar

Search

CALCULATORS

  • Expected DA Calculator from July 2023
  • 7th pay commission calculator [updated]
  • Salary Hike Calculator for Government Employees
  • Promotion/MACP Option form Calculator
  • Next MACP Calculator
  • 7th Pay Commission Pension Calculator
  • GPF Interest Calculator 2022-23
  • Age Calculator
  • Gratuity Calculator
  • HRA Exemption Calculator

Pay Matrix

  • Defence Personnel
  • MNS Officers
  • Tamil nadu
  • Rajasthan
  • Odisha
  • Gujarat
  • Haryana
  • Jharkhand
  • Madhya Pradesh
  • Nagaland
  • Tripura
  • Uttrakhand
  • Assam
  • Bihar
  • CSD Car Price List 2023
  • Maruti CSD Car Price
  • afd.csdindia.gov.in login

Secondary Sidebar

Recent Posts

  • Vigilance-Based System Enhancements for OBHS Staff
  • Approval of Postal Sub-Divisions for Village Banking – DOP
  • SSA Operation in Cases of Gender Change – DOP
  • Clarification on Promotional and Incentive Structure for PLI/RPLI
  • SOP for Non-Migrated Certificates in Finacle CBS

Footer

Copyright© 2010–2023

Central Government Employees News - Govtempdiary